pelitrexol
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2001 (NCT00017524)
Timeline
Indications
Mechanism of action
- GAR transformylaseINHIBITOR
GAR transformylase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)sc1CC[C@@H]1CNc2nc(N)[nH]c(=O)c2C1- Mol. weight
- 463.52 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2107361 ↗
Also known as
- ag2037
- ag2037
- ag-2037
- ag-2037
- pelitrexol
- pelitrexol
- pelitrexol
- pelitrexol
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00090701 | Phase 2 | Sep 1, 2004 | Pfizer |
| NCT00078468 | Phase 2 | Dec 1, 2003 | Pfizer |
| NCT00017524 | Phase 1 | Mar 1, 2001 | National Cancer Institute (NCI), University of Alabama, Birmingham |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 2 | 2 | 1 | 2003 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2001 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 1 | 1 | 2001 |
3 organizations
Page 1 / 1